APG Asset Management N.V. Sells 1,634 Shares of Insulet Corporation $PODD

Key Points

• APG Asset Management N.V. reduced its stake in Insulet Corporation ($PODD) by 3.9%, selling 1,634 shares, and now holds 39,828 shares worth $9.68 million.
• Insulet's recent quarterly earnings showed a notable 32.9% year-over-year revenue increase to $649.10 million, with an EPS of $1.17 exceeding analyst expectations.
• Analysts maintain a positive outlook on Insulet, with 16 out of 18 analysts rating the stock as a Buy and a consensus target price of $332.71.

APG Asset Management N.V. lessened its holdings in Insulet Corporation (NASDAQ:PODD - Free Report) by 3.9% during the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 39,828 shares of the medical instruments supplier's stock after selling 1,634 shares during the quarter. APG Asset Management N.V. owned about 0.06% of Insulet worth $9,683,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Smartleaf Asset Management LLC lifted its stake in shares of Insulet by 23.1% in the first quarter. Smartleaf Asset Management LLC now owns 490 shares of the medical instruments supplier's stock worth $127,000 after buying an additional 92 shares in the last quarter. Sax Wealth Advisors LLC grew its stake in Insulet by 5.7% during the first quarter. Sax Wealth Advisors LLC now owns 3,217 shares of the medical instruments supplier's stock valued at $845,000 after acquiring an additional 173 shares in the last quarter. AlphaQuest LLC lifted its position in Insulet by 23.3% during the first quarter. AlphaQuest LLC now owns 1,590 shares of the medical instruments supplier's stock valued at $418,000 after purchasing an additional 300 shares during the last quarter. 1832 Asset Management L.P. bought a new position in Insulet during the first quarter valued at $3,428,000. Finally, Norinchukin Bank The lifted its position in Insulet by 15.2% during the first quarter. Norinchukin Bank The now owns 3,612 shares of the medical instruments supplier's stock valued at $949,000 after purchasing an additional 476 shares during the last quarter.

Insulet Trading Up 1.0%

PODD traded up $3.25 on Thursday, reaching $337.60. 457,992 shares of the company traded hands, compared to its average volume of 714,523. Insulet Corporation has a one year low of $199.68 and a one year high of $337.84. The firm has a fifty day simple moving average of $303.31 and a two-hundred day simple moving average of $287.23. The company has a market cap of $23.76 billion, a P/E ratio of 102.61, a price-to-earnings-growth ratio of 2.80 and a beta of 1.35. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64.

Insulet (NASDAQ:PODD - Get Free Report) last posted its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 EPS for the quarter, beating analysts' consensus estimates of $0.92 by $0.25. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The business had revenue of $649.10 million for the quarter, compared to the consensus estimate of $612.31 million. During the same quarter last year, the firm posted $0.55 EPS. The company's revenue for the quarter was up 32.9% on a year-over-year basis. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, equities research analysts expect that Insulet Corporation will post 3.92 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have commented on PODD. Wall Street Zen upgraded shares of Insulet from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Citigroup restated a "buy" rating on shares of Insulet in a report on Tuesday, July 8th. The Goldman Sachs Group assumed coverage on shares of Insulet in a report on Friday, May 30th. They issued a "buy" rating and a $380.00 target price for the company. Barclays raised their target price on shares of Insulet from $266.00 to $300.00 and gave the stock an "equal weight" rating in a report on Thursday, August 21st. Finally, Truist Financial assumed coverage on shares of Insulet in a report on Monday, June 16th. They issued a "buy" rating and a $365.00 target price for the company. Sixteen research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $332.71.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.